Guardant’s blood test tracks microsatellite instability status on par with tissue biopsy in new study

In a trial involving 949 patients with 40 tumor types, including gastric cancer, a blood test from Guardant Health was as good as biopsy at finding the biomarker MSI, which predicts a strong response to immunotherapy.